A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

por Lévy, V, Zohar, S, Bardin, C, Vekhoff, A, Chaoui, D, Rio, B, Legrand, O, Sentenac, S, Rousselot, P, Raffoux, E, Chast, F, Chevret, S, Marie, J P
Publicado 2006

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER...

por Raffoux, E., De Botton, S., Ades, L., Carré, M., Cluzeau, T., Saillard, C., Heiblig, M., Beckerich, F., Gastaud, L., Dupuis, A., Richez, U., Dumas, P.-Y.
Publicado 2022

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

por Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Publicado 2015